2025-04-17 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Analysis

**0. Summary of Key Figures:**

* **Cumulative Return (TEVA):** 29.91%
* **Cumulative Return (VOO/S&P 500):** 76.08%
* **Return Difference (TEVA vs VOO):** -46.2%
* **Relative Divergence:** 55.8% (indicates TEVA's underperformance relative to its historical range against VOO)
* **Current Price:** $13.43
* **5-Day Moving Average:** $13.38
* **20-Day Moving Average:** $14.68
* **60-Day Moving Average:** $16.39
* **RSI:** 31.67 (Suggests oversold conditions)
* **PPO:** -0.57 (Indicates bearish momentum)
* **Market Risk Indicator (MRI):** 0.41 (Medium Risk)
* **Expected Return (Long-Term):** -59.8% (significantly underperforming S&P 500 over the long term)


**1. Company Overview and Performance Comparison:**

Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company.  Its cumulative return significantly lags the S&P 500 (VOO) over the analyzed period. The -46.2% difference highlights substantial underperformance.  The relative divergence of 55.8% indicates that this underperformance is relatively significant compared to its historical volatility against the S&P 500.

**Alpha and Beta Analysis:**  The provided data shows inconsistent alpha and highly volatile beta values.  While some periods show positive CAGR,  the alpha is consistently negative, suggesting underperformance relative to the market, even during periods of positive growth. The high and fluctuating beta indicates significant sensitivity to market movements.


**2. Recent Price Movement:**

The current price ($13.43) is below all three moving averages (5-day, 20-day, 60-day), suggesting a bearish trend.  The recent price drop of $0.17 (-1.25%) from the previous close further confirms this short-term bearish trend.


**3. Technical Indicators and Relative Divergence:**

The RSI of 31.67 indicates the stock is currently in oversold territory, suggesting potential for a short-term bounce. However, the negative PPO (-0.57) suggests bearish momentum. The recent negative relative divergence (-2.5) reinforces the short-term downward trend. The MRI of 0.41 suggests a medium level of risk. The significant negative expected return (-59.8%) indicates a substantial underperformance compared to the S&P 500 is expected over the long term (2+ years).


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -$0.39 | $4.33B       |
| 2024-07-31 | -$0.75 | $4.16B       |
| 2024-05-08 | -$0.12 | $3.82B       |
| 2023-11-09 | $0.07  | $3.85B       |
| 2024-02-12 | $0.06  | $3.85B       |

Recent earnings show significant volatility, with both positive and negative EPS. Revenue has been relatively stable, but the inconsistent profitability is a concern.  The negative EPS in several recent quarters is particularly troubling.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.23B | 50.15%       |
| 2024-09-30 | $4.33B | 49.60%       |
| 2024-06-30 | $4.16B | 48.61%       |
| 2024-03-31 | $3.82B | 46.37%       |
| 2023-12-31 | $4.46B | 54.18%       |

Revenue shows some fluctuations but generally remains relatively consistent. Profit margins are also fluctuating, exhibiting a downward trend in recent quarters.

**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2024-12-31 | $5.37B  | -4.04%  |
| 2024-09-30 | $6.07B  | -7.21%  |
| 2024-06-30 | $6.36B  | -13.30% |
| 2024-03-31 | $7.28B  | -1.91%  |
| 2023-12-31 | $7.51B  | 5.72%   |

Equity has decreased, and the ROE has turned negative in recent quarters, indicating a decline in profitability and possibly financial distress.  The significant negative ROE values raise serious concerns about the company's financial health.


**6. Overall Analysis:**

TEVA's performance significantly lags the S&P 500, exhibiting a clear pattern of underperformance.  Technical indicators suggest oversold conditions but also bearish momentum.  Recent earnings reveal inconsistent profitability with several quarters reporting negative EPS, and financial statements show a troubling decline in ROE and equity.  The high beta suggests significant market risk.  The projected long-term underperformance relative to the S&P 500 (-59.8%) reinforces the overall negative outlook.  Further investigation into the reasons for the company's underperformance and financial health is recommended before considering any investment.  The current situation suggests a high level of risk.
